IP Library Granted Patent US 10,119,133
Granted Patent B2
US 10,119,133 · App. 14/775,930 · Granted Nov 6, 2018

Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing

Inventors: J. Keith Joung (Winchester, MA); Jeffry D. Sander (Ames, IA); Yan-fang Fu (Malden, MA); Morgan Maeder (Brookline, MA)
Assignee: The General Hospital Corporation
C12N15/102C07K14/005C07K14/195C12N9/0071C12N9/1007C12N9/16C12N9/22C12N9/96C12N15/01C12N15/63C12N15/85C12Y301/21004C07K2319/00C07K2319/01C12N2710/00033C12N2770/00033C12N2800/80C12Y114/11C12Y201/01C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,119,133
App. No.
14/775,930
Granted
Nov 6, 2018
Kind
B2
Abstract

CRISPR-Cas genome editing uses a guide RNA, which includes both a complementarity region, which binds the target DNA by base-pairing, and a Cas9-binding region, to direct a Cas9 nuclease to a target DNA. Further disclosed are methods for increasing specificity of RNA-guided genome editing using CRISPR/Cas9 systems by using truncated guide RNAs (tru-gRNAs).

Claims (18)

1. A method of increasing specificity of S. pyogenes CRISPR-Cas9 (Cas9) RNA-guided genome editing in a cell, the method comprising contacting the cell with a guide RNA that includes a complementarity region at the 5′ end of the guide RNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a selected target genomic sequence, wherein the selected target genomic sequence is immediately 5′ of a protospacer adjacent motif (PAM), the guide RNA comprises

SEQ ID NO:4, and wherein in the presence of a S. pyogenes Cas9 genome editing enzyme, the guide RNA complementarity region binds and directs the Cas9 genome editing enzyme to the selected target genomic sequence, thereby increasing specificity of RNA-guided genome editing in a cell.

2. A method of inducing a break in a target region of a double-stranded DNA molecule in a cell, the method comprising expressing in or introducing into the cell:

a S. pyogenes CRISPR/Cas9 nuclease or nickase; and

a guide RNA that includes a complementarity region at the 5′end of the guide RNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a double-stranded DNA molecule comprising a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif (PAM), and wherein the guide RNA complementarity region binds and directs the Cas9 nuclease or nickase to the target region of a double-stranded DNA molecule, and wherein the guide RNA comprises

SEQ ID NO:4, thereby inducing a break in the target region of a double-stranded DNA molecule in a cell.

3. A method of modifying a target region of a double-stranded DNA molecule in a cell, the method comprising expressing in or introducing into the cell:

a S. pyogenes CRISPR dCas9-heterologous functional domain fusion protein (dCas9-HFD); and

a guide RNA that includes a complementarity region at the 5′end of the guide RNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a selected target sequence present on a double-stranded DNA molecule, wherein the selected target sequence is immediately 5′ of a protospacer adjacent motif (PAM), the guide RNA comprises

SEQ ID NO:4, and wherein the guide RNA complementarity region binds and directs the dCas9-HFD to the selected target sequence, thereby modifying a target region of a double-stranded DNA molecule in a cell.

4. The method of claim 1 , wherein the target region is in a target genomic sequence.

5. The method of claim 3 , wherein dCas9-HFD comprises a heterologous functional domain (HFD) that modifies gene expression, histones, or DNA.

6. The method of claim 5 , wherein the HFD is a transcriptional activation domain, an enzyme that catalyzes DNA demethylation, an enzyme that catalyzes histone modification, or a transcription silencing domain.

7. The method of claim 6 , wherein the transcriptional activation domain is from activator domain VP64 or NF-kappa B subunit p65 (NF-κB p65).

8. The method of claim 6 , wherein the enzyme that catalyzes histone modification is lysine-specific histone demethylase 1 (LSD1), a histone methyltransferase (HNMT), histone acetyltransferase (HAT), histone deacetylase (HDAC), or histone demethylase.

9. The method of claim 6 , wherein the transcription silencing domain is from Heterochromatin Protein 1 alpha (HP1α) or Heterochromatin Protein 1 beta (HP1β).

10. The method of claim 1 , wherein the cell is a eukaryotic cell.

11. The method of claim 10 , wherein the cell is a mammalian cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2017
From: JOUNG, J. KEITH; SANDER, JEFFRY D.; FU, YAN-FANG; MAEDER, MORGAN
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 042882/0286 →
CONFIRMATORY LICENSE Recorded Oct 22, 2015
From: MASSACHUSETTS GENERAL HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036931/0799 →
Continuity (5)
Provisional Application 61799647 · Mar 15, 2013
Provisional Application 61838178 · Jun 21, 2013
Provisional Application 61838148 · Jun 21, 2013
Provisional Application 61921007 · Dec 26, 2013
Related Publication 20160024523A1 · Jan 28, 2016
Cited By (5)
US 12,201,699 US 12,215,343 US 12,286,727 US 12,297,466 US 12,338,436